Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression:
Overview
- Phase
- Not Applicable
- Intervention
- Dental pulp mesenchymal cell injection
- Conditions
- Depression
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
- Enrollment
- 48
- Primary Endpoint
- The total score of Montgomery Asperger Depression Scale (MADRS) decreased from baseline after 8 weeks of treatment
- Last Updated
- 4 years ago
Overview
Brief Summary
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression 8 weeks after administration
Detailed Description
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression 8 weeks after administration. The positive control drug was fluoxetine hydrochloride capsule with a dose of 40mg / day.The study included screening period (no more than 4 weeks), treatment period (8 weeks), and follow-up period (12 months).Subjects who met the inclusion criteria and did not meet the exclusion criteria were randomly assigned to the experimental group and the control group in the ratio of 1:1.During 8 weeks of treatment, subjects in the experimental group were given dental pulp mesenchymal cell injection + fluoxetine hydrochloride capsule simulant; The subjects in the control group were given dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule. During the treatment period, dental pulp mesenchymal cell injection / vehicle was injected intravenously for 4 times at an interval of 2 weeks (once at 0, 2, 4 and 6 weeks respectively); At the same time, fluoxetine hydrochloride capsule / simulant was taken orally every day during the treatment period.The efficacy and safety were evaluated 2 weeks after intravenous administration (visit and evaluation at 2, 4, 6 and 8 weeks respectively). Safety telephone follow-up was conducted 4 weeks (10th week), 6 months and 12 months after the last intravenous administration.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At the time of signing the informed consent form, the age of 18 ≤ 60, regardless of gender.
- •18.5kg/m2 ≤ body mass index (BMI) ≤ 35kg / m2, male weight ≥ 50kg, female weight ≥ 45kg.
- •Women of childbearing age need to be able to ensure effective contraception (medically approved contraceptive measures, such as intrauterine device, contraceptive pill or condom) during the trial and within 3 months after the end of the trial.
- •According to the diagnostic criteria of diagnostic and Statistical Manual of mental disorders (5th Edition) (dsm-5), it was diagnosed as severe depressive disorder, marked as moderate or severe, and without psychotic characteristics.
- •The total score of Montgomery Asperger Depression Scale (MADRS) in screening period and baseline was ≥ 22, and the CGI-S score was ≥
- •Compared with the screening period, the change in the total MADRS score at baseline did not exceed 25% of the screening period.
- •The patients fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the written informed consent, and are willing to complete the whole trial process according to the trial requirements.
Exclusion Criteria
- •It meets dsm-5 diagnostic criteria for other mental disorders.
- •A depressive episode secondary to physical or other mental illness.
- •The researchers determined that there was a high risk of suicide: there were serious suicides and self injuries within 1 month before or during the screening; Or those who answered "yes" to item 5 of "suicidal ideation" in the screening Columbia suicide severity rating scale (c-ssrs).
- •The depressive episode is ineffective after sufficient treatment with one or more antidepressants (at least 6 weeks according to the dosage in the manual).
- •Those who had received electroconvulsive therapy (ECT) within 1 month before screening.
- •Patients who have received other stem cell therapy.
- •Have a history of infection within 1 month before screening and need hospitalization and / or antibiotic treatment; Or currently using systemic sex hormones (glucocorticoids), immunosuppressants or cytotoxic therapy.
- •Screening the patients who had been diagnosed with hyperthyroidism or hypothyroidism within the previous year and are still taking drugs; Or have a history of thyroid disease and thyroid stimulating hormone (TSH) is higher than 1.2 times the upper limit of normal value or lower than 0.8 times the lower limit of normal value;
- •Patients with a history of epilepsy (excluding children's history of fever and convulsion).
- •Persons with severe alcohol or drug dependence within 1 year before screening (excluding caffeine or nicotine); Or daily alcohol intake of or above 5 units (1 units =360mL wine or 45mL Baijiu or 120mL wine).
Arms & Interventions
Test group
Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride
Intervention: Dental pulp mesenchymal cell injection
Test group
Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride
Intervention: fluoxetine hydrochloride capsule
control group
Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule
Intervention: Dental pulp mesenchymal cell vehicle
control group
Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule
Intervention: fluoxetine hydrochloride capsule
Outcomes
Primary Outcomes
The total score of Montgomery Asperger Depression Scale (MADRS) decreased from baseline after 8 weeks of treatment
Time Frame: 8 weeks
Secondary Outcomes
- Effective rate of treatment (effective: the total score of MADRS decreased by ≥ 50% compared with baseline)(8 weeks)
- Remission rate of treatment (remission: MADRS total score ≤ 11 points)(8 weeks)